STELLA PHARMA CORPORATION
4888・Growth Market・Pharmaceuticals
Governance
The company has adopted an audit and supervisory committee structure (7 directors, of which all 3 outside directors serve as audit and supervisory committee members). It has established a Nomination and Compensation Committee (composed of a majority of outside directors), building a highly transparent and objective decision-making framework. During the fiscal year under review, the Board of Directors met 21 times, with all directors attending every meeting.
Risk Management
The company has established a Risk Management Committee (convened at least once every half-year) and a Compliance Committee to identify, assess, and design countermeasures for risks. The Internal Audit Office, reporting directly to the President and Representative Director, conducts regular audits of each department, establishing a system for early detection and reporting. Sustainability-related risks are also managed collectively by this committee.
Shareholder Returns
The annual dividend remains ¥0.00 (no dividend) for both FY2026 (ending March 2026) and FY2027 (ending March 2027). With no distributable financial resources currently available, the company's policy is to consider implementing dividends once profitability stabilizes, after weighing the balance between R&D investment, retained earnings, and shareholder returns. No share buybacks have been conducted.
Dividend Policy
The annual dividend is ¥0.00 (no dividend) for FY2025 (ended March 2025), FY2026 (ending March 2026), and FY2027 (ending March 2027, forecast). The company currently has no distributable financial resources and therefore pays no dividend. Going forward, once the pharmaceutical business achieves stable profitability and a sound financial position, the company will appropriately determine whether to implement dividends after weighing the balance between new R&D investment, retained earnings, and shareholder returns.
ESG
The Sustainability Promotion Team, positioned directly under the Representative Director, formulates policy and strategy, with the Board of Directors approving and overseeing the framework. The company has established five materiality issues related to the SDGs and is promoting human resource development and diverse working arrangements (flextime, telework, childcare and family care leave). Quantitative ESG indicators and targets have not yet been set, with plans to formulate them in the future.
Last updated: June 23, 2026